Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.

PubWeight™: 1.30‹?› | Rank: Top 10%

🔗 View Article (PMC 1737395)

Published in J Neurol Neurosurg Psychiatry on June 01, 2001

Authors

A J Green1, E J Thompson, G E Stewart, M Zeidler, J M McKenzie, M A MacLeod, J W Ironside, R G Will, R S Knight

Author Affiliations

1: The National Creutzfeldt-Jakob Disease Surveillance Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. Alison.Green@ed.ac.uk

Articles citing this

S100B Protein as a Post-traumatic Biomarker for Prediction of Brain Death in Association With Patient Outcomes. Arch Trauma Res (2013) 1.44

A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2003) 1.27

Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Res (2008) 1.15

Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol (2006) 1.06

Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol (2010) 0.96

Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. J Neurol (2009) 0.94

Variant CJD. 18 years of research and surveillance. Prion (2014) 0.93

Re-assessment of PrP(Sc) distribution in sporadic and variant CJD. PLoS One (2013) 0.92

Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. J Neurol Neurosurg Psychiatry (2006) 0.87

Application of "omics" to prion biomarker discovery. J Biomed Biotechnol (2010) 0.86

Recent US Case of Variant Creutzfeldt-Jakob Disease-Global Implications. Emerg Infect Dis (2015) 0.86

The molecular epidemiology of variant CJD. Int J Mol Epidemiol Genet (2011) 0.84

Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders. NeuroRx (2006) 0.82

Biomarkers of Brain Damage: S100B and NSE Concentrations in Cerebrospinal Fluid-A Normative Study. Biomed Res Int (2015) 0.81

Cerebrospinal Fluid Studies in Kenyan Children with Severe Falciparum Malaria. Open Trop Med J (2008) 0.80

Sporadic Creutzfeldt-Jakob disease: early signs and pre-mortem diagnosis. BMJ Case Rep (2009) 0.78

14-3-3s are potential biomarkers for HIV-related neurodegeneration. J Neurovirol (2012) 0.78

Comparative peptidome analyses of the profiles of the peptides ranging from 1-10 KD in CSF samples pooled from probable sporadic CJD and non-CJD patients. Prion (2012) 0.76

Alien hand and leg as the presenting feature of probable sporadic Creutzfeldt-Jakob disease: A rare presentation of a rare disease. Ann Indian Acad Neurol (2015) 0.75

Articles cited by this

A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 20.15

The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med (1996) 5.06

Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol (2000) 2.42

Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol (1998) 2.35

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem (1993) 2.18

S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke (1987) 1.96

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology (1997) 1.78

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett (1997) 1.71

New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet (1997) 1.70

Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol (1996) 1.56

New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet (1997) 1.55

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol (1995) 1.46

Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology (2000) 1.36

Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. BMJ (1997) 1.27

Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun (1997) 1.24

S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol (1997) 1.24

14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord (1999) 1.19

Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet (1995) 1.17

14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients. Neurology (2000) 1.14

Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol (1999) 1.11

High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta (1992) 1.02

A specific and sensitive ELISA for measuring S-100b in cerebrospinal fluid. J Immunol Methods (1997) 0.99

Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci (1983) 0.97

Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J Clin Neurosci (2000) 0.97

Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett (1999) 0.97

14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet (2000) 0.94

Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett (1997) 0.85

Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology (2000) 0.84

Neuropathological findings in new variant CJD and experimental transmission of BSE. FEMS Immunol Med Microbiol (1998) 0.83

Increased CSF tau protein in corticobasal degeneration. J Neurol (1998) 0.79

Articles by these authors

A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 20.15

Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 15.73

Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain (2009) 5.03

Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet (2004) 4.85

Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet (1997) 4.28

Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet (1999) 4.02

"Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet (1992) 3.74

Geographical distribution of variant CJD in the UK (excluding Northern Ireland). Lancet (1999) 3.39

Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol (2006) 3.29

Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology (2000) 3.23

Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11

Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet (1998) 3.08

Predicting the CJD epidemic in humans. Nature (1997) 3.04

Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 3.03

Creutzfeldt-Jakob disease and blood transfusion. Lancet (1993) 2.97

The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet (2000) 2.92

Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80

A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: Clinical features. J Neurol Neurosurg Psychiatry (1984) 2.68

Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis (2001) 2.62

Retrospective study of prion-protein accumulation in tonsil and appendix tissues. Lancet (2000) 2.59

Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain (2006) 2.54

Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A (2000) 2.46

Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol (2000) 2.42

CSF opening pressure: reference interval and the effect of body mass index. Neurology (2006) 2.39

The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry (2010) 2.29

Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (1982) 2.15

Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10

Deaths from variant Creutzfeldt-Jakob disease. Lancet (1999) 2.04

Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders. Haemophilia (2010) 2.03

Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02

High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol (1997) 2.00

Humoral factors in the pathogenesis of Graves' disease. Physiol Rev (1968) 1.98

Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet (2001) 1.97

Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain (2004) 1.96

Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology (2005) 1.88

Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry (1988) 1.87

Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet (2001) 1.84

Sporadic Creutzfeldt-Jakob disease in a 18-year-old in the UK. Lancet (1995) 1.76

Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang (2006) 1.76

Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73

Underenumeration in the 1991 census. BMJ (1993) 1.71

Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol (1993) 1.71

New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests. Lancet (1997) 1.70

Amount of research interest in rare and common neurological conditions: bibliometric study. BMJ (2001) 1.68

The dietary intake of children with IDDM. Diabetes Care (1996) 1.67

Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol (1996) 1.66

Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol (1992) 1.66

Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem (1997) 1.63

MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology (2009) 1.61

Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet (1998) 1.60

Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58

New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet (1997) 1.55

Creutzfeldt-Jakob disease and the eye. II. Ophthalmic and neuro-ophthalmic features. Eye (Lond) (2000) 1.53

Tissue and organ donation for research in forensic pathology: the MRC Sudden Death Brain and Tissue Bank. J Pathol (2007) 1.51

Iatrogenic Creutzfeldt-Jakob disease: an example of the interplay between ancient genes and modern medicine. Neurology (1994) 1.50

Gliosarcoma with areas of primitive neuroepithelial differentiation and extracranial metastasis. Clin Neuropathol (2001) 1.49

Complex segregation analysis of antibodies to thyroid peroxidase in Old Order Amish families. Am J Med Genet (1993) 1.46

Isoelectric focusing versus quantitative measurements in the detection of intrathecal local synthesis of IgG. Clin Chim Acta (1990) 1.45

Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia (2010) 1.45

Selenium deficiency in total parenteral nutrition. Am J Clin Nutr (1979) 1.43

Variant CJD and blood transfusion: are there additional cases? Vox Sang (2014) 1.42

Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet (1999) 1.42

Dynamics of reactive oxygen intermediate production in human glioma: n-6 essential fatty acid effects. Eur J Clin Invest (1999) 1.42

Risk factors for variant Creutzfeldt-Jakob disease in dental practice: a case-control study. Br Dent J (2012) 1.42

Oligoclonal immunoglobulins and plasma cells in spinal fluid of patients with multiple sclerosis. Br Med J (1979) 1.41

Inactivation of metronidazole by aerobic organisms. J Antimicrob Chemother (1979) 1.41

In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc. J Pathol (2007) 1.41

Codon 129 genotype and new variant CJD. Lancet (1997) 1.40

Vaccines and variant CJD. Vaccine (2000) 1.40

Growth of hypercholesterolemic children completing physician-initiated low-fat dietary intervention. J Pediatr (1998) 1.40

Inhalational induction with sevoflurane in an adult with severe complex central airways obstruction. Anaesth Intensive Care (1997) 1.39

A thyroid-stimulating life: an interview with Dr. J. Maxwell McKenzie. Thyroid (2001) 1.39

Progressive ataxia, focal seizures, and malabsorption syndrome in a 41 year old woman. J Neurol Neurosurg Psychiatry (1996) 1.39

Lack of serum oligoclonal antibody responses to Chlamydophila pneumoniae in multiple sclerosis. Eur Neurol (2005) 1.38

Creutzfeldt-Jakob disease: implications for gastroenterology. Gut (2002) 1.38

Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38

Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. Lancet (1996) 1.37

Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology (2000) 1.34

Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study. Lancet (2000) 1.34

Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab (1983) 1.33

A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. J Neurol Sci (1977) 1.32